AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

Kiwi's wings clipped, could break back below 60 US cents
Economy

Kiwi's wings clipped, could break back below 60 US cents

The NZ dollar is trading around a seven-week low. 

Synlait lifts 2024/25 forecast milk price
Primary Sector

Synlait lifts 2024/25 forecast milk price

Its $9 per kilogram of milk solids is in line with Fonterra's midpoint.

Why Pacific Equity Partners loves buying in NZ
Markets

Why Pacific Equity Partners loves buying in NZ

There are clear reasons why PEP did its first deal here, Cameron Blanks says.

NZX main board to get bitcoin ETF
Markets

NZX main board to get bitcoin ETF

NZX-owned fund manager Smart has teamed up with US investment giant Black Rock.